(VIANEWS) – The Market ended the session with GALAPAGOS (GLPG.AS) rising 10.54% to €25.80 on Monday while AEX-Index dropped 0.12% to €907.49.
GALAPAGOS’s last close was €23.34, 40.15% below its 52-week high of €39.00.
About GALAPAGOS
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Earnings Per Share
As for profitability, GALAPAGOS has a trailing twelve months EPS of €0.48.
PE Ratio
GALAPAGOS has a trailing twelve months price to earnings ratio of 53.75. Meaning, the purchaser of the share is investing €53.75 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.15%.
Yearly Top and Bottom Value
GALAPAGOS’s stock is valued at €25.80 at 22:32 EST, way below its 52-week high of €39.00 and way higher than its 52-week low of €22.38.
More news about GALAPAGOS (GLPG.AS).
